<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="14785">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01688908</url>
  </required_header>
  <id_info>
    <org_study_id>201202014</org_study_id>
    <nct_id>NCT01688908</nct_id>
  </id_info>
  <brief_title>Efficacy of Endoscopy Screening on Esophageal Cancer in China (ESECC)</brief_title>
  <acronym>ESECC</acronym>
  <official_title>Efficacy of Endoscopy Screening on Esophageal Cancer in a High Risk Region of Rural China: a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University</source>
  <oversight_info>
    <authority>China: Ministry of Health</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purposes of this study are as follows:

        1. Establish clinical criteria of endoscopy screening on esophageal cancer in high risk
           region of China;

        2. Evaluate the efficacy of endoscopy screening on esophageal cancer;

        3. Determine the most cost-effective strategy of endoscopy  screening in high risk
           population of China.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Screening</study_design>
  <primary_outcome>
    <measure>Esophageal cancer specific mortality</measure>
    <time_frame>5-10 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of advanced esophageal cancer</measure>
    <time_frame>5-10 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Cost of saving 1 person-year of life</measure>
    <time_frame>5-10 years</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">32000</enrollment>
  <condition>Esophageal Squamous Cell Carcinomas</condition>
  <arm_group>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participants in this arm will not accept the endoscopy screening. And only baseline and follow-up interview and an alternative abdominal ultrasound scan will be conducted in this arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Screening Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this arm will accept a baseline endoscopy screening and questionnaire investigation and follow-up interview. If applicable, all participants in this arm will accept a second endoscopy screening in the 5th year of the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Endoscopy Screening</intervention_name>
    <description>Upper G.I. endoscopy examination with Lugols Iodine in esophagus
Biopsy at the visually abnormal sites
Pathologic examination of all biopsy tissue specimens
Advise of regular re-examination will be given to participants who are diagnosed of moderate and severe dysplasia.
Advises of endoscopic or surgical treatment will be given to participants who are diagnosed of early upper G.I. carcinomas.</description>
    <arm_group_label>Screening Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. permanent residency in one of the 334 target villages which were randomly selected
             from all the 968 villages of Hua County of Anyang, China;

          2. age between 40 and 69 years;

          3. willingness to participate in this study and complete all parts of the examination.

        Exclusion Criteria:

          1. self-reported history of cancer, cardiovascular disease, mental disorder, or other
             contraindications for endoscopy;

          2. self-reported history of infection with hepatitis B virus (HBV), hepatitis C virus
             (HCV), or human immunodeficiency virus (HIV), and any evidence of these infections
             based on serum screening;

          3. history of endoscopy examination within 5 years prior to the interview.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yang Ke, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hong Cai, M.D.</last_name>
    <phone>8610-88196762</phone>
    <email>drhcai@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zhonghu He, Ph.D.</last_name>
    <phone>8610-88196762</phone>
    <email>zhonghuhe@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Laboratory of Genetics, Beijing Cancer Hospital and Institute, Peking University</name>
      <address>
        <city>Beijing</city>
        <state>Bejing</state>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hong Cai, M.D.</last_name>
      <phone>8610-88196762</phone>
      <email>drhcai@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Zhonghu He, Ph.D.</last_name>
      <phone>8610-88196762</phone>
      <email>zhonghuhe@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Hong Cai, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <lastchanged_date>September 17, 2012</lastchanged_date>
  <firstreceived_date>September 17, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University</investigator_affiliation>
    <investigator_full_name>Yang Ke</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Esophageal Squamous Cell carcinomas</keyword>
  <keyword>Endoscopy Screening</keyword>
  <keyword>High risk region</keyword>
  <keyword>China</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
